Pricing Log in Create free account

Caribou Biosciences, Inc. (CRBU) vs Kalaris Therapeutics Inc. (KLRS)

Caribou Biosciences, Inc. and Kalaris Therapeutics Inc. are both Biotechnology companies. Caribou Biosciences, Inc. and Kalaris Therapeutics Inc. are of similar size ($49.8M and $47.8M). Kalaris Therapeutics Inc. has the higher net margin (0.00% vs −1,030.4%) and the higher return on invested capital (0.00% vs 0.00%). Across the 13 metrics below, Kalaris Therapeutics Inc. leads on 9 and Caribou Biosciences, Inc. on 4.

Valuation

Metric CRBU KLRS Biotechnology median
P/E n/m n/m 8.50
P/S 4.73 n/m 9.71
P/B 0.48 0.83 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA 0.60 0.55 0.64
EV/Sales (6.46) n/m 9.21
Earnings yield (229.79%) (101.00%) (33.15%)
Free cash flow yield (279.78%) (85.89%) (25.50%)

Profitability

Metric CRBU KLRS Biotechnology median
Gross margin 100.00% 0.00% 65.16%
Operating margin (1,090.90%) 0.00% 0.00%
Net margin (1,030.42%) 0.00% 0.00%
Free cash flow margin (1,323.30%) 0.00% 0.00%
Return on equity (78.27%) (79.91%) (56.36%)
Return on assets (56.87%) (46.02%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CRBU KLRS Biotechnology median
Revenue growth (TTM) 10.02% — 6.02%
EPS growth (last fiscal year) 3.64% 94.50% 30.26%
Revenue growth, 5-year CAGR (2.03%) — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CRBU KLRS Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 6.49 10.98 4.72
Net debt to EBITDA 0.96 2.54 0.96

Dividend

Metric CRBU KLRS Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric CRBU KLRS Biotechnology median
Market cap 49.82m 47.83m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack